Recurrent Vulvovaginal Candidiasis Market
Number of pages: 100 | Report Format: PDF | Published date: April 27, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.02 billion |
|
Revenue Forecast in 2031 |
US$ 1.48 billion |
|
CAGR |
4.2% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global recurrent vulvovaginal candidiasis market was valued at US$ 1.02 billion in 2022 and is expected to register a revenue CAGR of 4.2% to reach US$ 1.48 billion by 2031.
Recurrent Vulvovaginal Candidiasis Market Fundamentals
Vulvovaginal Candidiasis (VVC) is often caused by Candida albicans; however, it can also be caused by other Candida species or yeasts. Pruritus, vaginal discomfort, dyspareunia, external dysuria, and atypical vaginal discharge are common signs of VVC. None of these symptoms are unique to VVC. An estimated 75% of women will experience at least one episode of VVC, with 40%-45% experiencing two or more episodes. Candida is a dimorphic fungus from the Ascomycota phylum that lives in the respiratory, gastrointestinal, and genitourinary tracts of more than 30% of healthy people throughout their lives. Depending on the affected location and the patient's health state, changes in the symbiotic interaction between the fungus and the mucosal ecology are linked with mild to moderate fungal dysbiosis.
Up to 9% of women in varied populations have three or four episodes in a year, known as recurrent vulvovaginal candidiasis (RVVC). Worldwide prevalence and epidemiological statistics are few and often erroneous since they are based on self-reports and local general practitioner diagnoses. The researcher systematically reviewed epidemiological studies from 1985 to 2016 and found a global annual prevalence of 3871 RVVC cases per 100,000 women, with the highest frequency (9%) in patients aged 25 to 34, based on 6000 online surveys from five Western European countries and the United States.
A broad spectrum of host-related predisposing variables, including type 2 diabetes, immunosuppressive regimens, antibiotic medication, and behavioral factors like contraception and intrauterine device usage, have been proposed to enhance the start of VVC. However, because approximately 20-30% of VVC patients are healthy women with no predisposing factors, it has been proposed that inter-individual differences such as genetic background and ethnicity, as well as Candida strain types and occurrence, may play a role in idiopathic RVVC pathogenesis.
Contraceptive methods may potentially encourage vulvovaginal candidiasis recurrence. Using spermicidal jellies and lotions increases vulnerability to infection by modifying vaginal flora and enhancing Candida organism adherence. Women who use oral contraceptives are more likely to develop vulvovaginal candidiasis. Candida cells, according to one idea, have estrogen and progesterone receptors that, when activated, enhance fungal growth. Women with recurrent vulvovaginal candidiasis may have a lack of cell-mediated immunity. People with acquired immunodeficiency syndrome are also vulnerable to systemic candidal infection. According to certain research, 40 to 70% of women with recurrent vulvovaginal candidiasis exhibit a particular energy that results in a subnormal T-lymphocyte response to Candida.
[34]
Recurrent Vulvovaginal Candidiasis Market Dynamics
According to an NCBI report, VVC is a prevalent fungus among women, impacting around 138 million women globally each year. Among the key drivers driving market development are a strong growing pipeline with recent approvals of medicines in disease management, increased illness burden, and the launch of novel pharmaceuticals such as BREXAFEMME and VIVJOA. VVC infection in women is on the rise globally, affecting about 75% of women who report illness incidence at least once in their lives.
According to an NCBI article, VVC affects 10-20% of women worldwide, with 9% reporting recurring VVC instances. Furthermore, the disease's incidence is increasing due to an increase in diabetes patients and an increase in antibiotic resistance instances among persons. Around 15% of such instances are also expected to necessitate particular treatment measures. As a result, the disease's increasing prevalence is propelling industrial expansion. The growing desire for better treatment choices drives R&D advancements, new medication approvals, and drug launches, generating a profitable potential for industry expansion. For instance, VIVJOA, an oral medication, obtained FDA clearance in August 2022. VIVJOA from Mycovia Pharmaceuticals is an antifungal that specifically inhibits fungus CYP5. Scynexis, Inc. announced the FDA clearance of their innovative medicine BREXAFEMME (Ibrexafungerp) for VVC therapy in June 2021.
Recurrent Vulvovaginal Candidiasis Market Ecosystem
The global recurrent vulvovaginal candidiasis market is analyzed from the following perspectives by drug class, route of administration, distribution channel, and region.
Recurrent Vulvovaginal Candidiasis Market by Drug Class
[45]
Based on the drug class, the global recurrent vulvovaginal candidiasis market is segmented into azoles, antibiotics, allylamines, and others.
The azole segment led the global market, accounting for the majority of total sales. For uncomplicated RVVC, topical azole antifungal agents are usually recommended as first-line therapy. For example, topical azoles, like clotrimazole or miconazole, are used for 7-14 days. Over-the-counter (OTC) options are available and may be effective for some women. Oral fluconazole is also an effective option for RVVC.
Recurrent Vulvovaginal Candidiasis Market by Rout of Administration
Based on the route of administration, the global recurrent vulvovaginal candidiasis market is segmented into oral, intravenous, and topical.
The oral segment dominated the market and accounted for the largest market share of total revenue. Because of the popular and simple mode of administration for azoles, excellent absorption, and usage of anti-fungal medications, it is expected to maintain its share during the projection period. Oral fluconazole is the most often used prescription medicine for treatment and maintenance therapy. It is also useful as a short-term treatment for recurrent VVC. The FDA recently authorized two oral dose regimens of VIVJOA (oteseconazole) to minimize the incidence of recurrent VVC. The topical category is predicted to develop at a consistent CAGR during the research period.
Recurrent Vulvovaginal Candidiasis Market by Distribution Channel
Based on the distribution channel, the global recurrent vulvovaginal candidiasis market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
Over the projected period, the retail pharmacy segment is expected to grow at the fastest CAGR. As illness treatment, control, and management require both short- and long-term pharmacological assistance, boosting the segment’s growth. Because the market contains both prescription and over-the-counter pharmaceuticals, pharmacists play a vital role in counseling patients and winning their trust. All of these reasons are projected to drive the segment's expansion.
Recurrent Vulvovaginal Candidiasis Market by Region
Based on region, the global recurrent vulvovaginal candidiasis market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa.
The North America region is predicted to continue to increase at a steady rate, retaining its leading position during the projection period. This dominance can be linked to greater regional patient awareness and healthcare spending. A recent Harvard research shows that roughly 6 million American women suffer from vulvodynia. The established healthcare infrastructures in this region, as well as the high prevalence of illness and the existence of key manufacturers, are essential factors contributing to the market share of vulvovaginal candidiasis therapy. Product approvals and launches for recurrent vulvovaginal candidiasis treatment are expected to drive the growth of North America's recurrent vulvovaginal candidiasis market. For example, Scynexis, Inc. announced FDA clearance for its innovative medication BREXAFEMME in June 2021.
Europe is one of the most important regions for recurrent vulvovaginal candidiasis treatment needs. The presence of a well-developed healthcare infrastructure and the availability of trained medical personnel improve the country's chances. Advanced therapy alternatives, new approvals and launches, and aggressive government initiatives all contribute to the expansion of the regional vulvovaginal candidiasis treatment market. Europe's market is likely to increase rapidly throughout the forecast period. The government bodies are increasing their investment in biopharmaceutical research and development in order to find solutions for rare diseases, which bodes well for the region's vulvovaginal candidiasis treatment system suppliers. The European market is quickly rising as the patient population grows, particularly in the United Kingdom and Germany. Advanced therapy choices, new approvals, launches, and aggressive government policies all help to drive regional market growth.
Asia Pacific, on the other hand, is expected to grow at the fastest rate throughout the projection years. The rapid growth rate can be ascribed to the increased disease burden of VVC as well as higher testing rates. Positive developments such as government healthcare benefits, improved consumer knowledge, and willingness to seek medical treatment are also projected to boost growth in the region.
Recurrent Vulvovaginal Candidiasis Competitive Landscape
To increase their market share, major companies are pursuing a variety of strategic measures such as regional growth, mergers, and acquisitions. Furthermore, firms are concentrating on obtaining approvals for innovative goods that have the potential to fulfill unmet requirements. For example, Mycovia Pharmaceuticals' VIVJOA, previously licensed in certain European, Asian, and Latin American nations, got FDA clearance in August 2022 for recurrent VVC therapy in the United States. Some of the prominent market players in the global recurrent vulvovaginal candidiasis market include,
Recurrent Vulvovaginal Candidiasis Strategic Development
Vulvovaginal Candidiasis (VVC) is often caused by Candida albicans; however, it can also be caused by other Candida species or yeasts. Up to 9% of women in varied populations have three or four episodes in a year, which is known as recurrent vulvovaginal candidiasis (RVVC).
North America is the key growth region in the global recurrent vulvovaginal candidiasis market.
With growing disease incidence and R&D advancements, the market is growing significantly.
The azole drug class segment led the global recurrent vulvovaginal candidiasis market.
Some prominent market players in the global recurrent vulvovaginal candidiasis market include Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd.
*Insights on financial performance are subject to the availability of information in the public domain